The Wall Street Journal @WSJ
Amgen’s $28 billion deal for rare-disease drugmaker Horizon Therapeutics could provide new sources of revenue for the biotech as patents expire on some big-selling products https://t.co/jAOmoOA1uZ — PolitiTweet.org
Created
Mon Dec 12 20:30:05 +0000 2022
Likes
22
Retweets
9
Source
SocialFlow
View Raw Data
JSON DataView on Twitter
Likely Available
The Wall Street Journal @WSJ
Amgen’s $28 billion deal for rare-disease drugmaker Horizon Therapeutics could provide new sources of revenue for the biotech as patents expire on some big-selling products https://t.co/jAOmoOA1uZ — PolitiTweet.org